Published in

BMJ Publishing Group, Thorax, 12(60), p. 1012-1018, 2005

DOI: 10.1136/thx.2005.045260

Elsevier, Year Book of Dermatology and Dermatologic Surgery, (2006), p. 50

DOI: 10.1016/s0093-3619(08)70008-x

Links

Tools

Export citation

Search in Google Scholar

Tumour necrosis factor (TNF ) as a novel therapeutic target in symptomatic corticosteroid dependent asthma

Journal article published in 2005 by P. H. Howarth ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Background: Tumour necrosis factor α (TNFα) is a major therapeutic target in a range of chronic inflammatory disorders characterised by a Th1 type immune response in which TNFα is generated in excess. By contrast, asthma is regarded as a Th2 type disorder, especially when associated with atopy. However, as asthma becomes more severe and chronic, it adopts additional characteristics including corticosteroid refractoriness and involvement of neutrophils suggestive of an altered inflammatory profile towards a Th1 type response, incriminating cytokines such as TNFα.